In This Article:
-
Cash and Cash Equivalents: $52.9 million as of December 31, 2024.
-
Fourth Quarter Revenue: $15 million, down from $73.5 million in Q4 2023.
-
Full-Year Revenue: $48 million for 2024, compared to $103.8 million in 2023.
-
R&D Expenses: $28.8 million for Q4 2024, up from $16.6 million in Q4 2023; $97 million for the full year 2024, up from $51.4 million in 2023.
-
G&A Expenses: $7.1 million for Q4 2024, compared to $6.4 million in Q4 2023; $23.7 million for the full year 2024, down from $25.6 million in 2023.
-
Net Loss: $20.7 million for Q4 2024 and $68.4 million for the full year 2024.
-
Diluted Net Loss Per Share: $0.38 for Q4 2024 and $1.27 for the full year 2024.
-
Net Income (Previous Year): $51.2 million for Q4 2023 and $22.8 million for the full year 2023.
-
Net Income Per Share (Previous Year): $0.96 for Q4 2023 and $0.43 for the full year 2023.
Release Date: March 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Spero Therapeutics Inc (NASDAQ:SPRO) is advancing its lead product candidate, tebipenem HBr, in a Phase 3 trial, which could become the first broad-spectrum oral carbapenem for complicated urinary tract infections.
-
The company has a partnership with GSK for the co-development of tebipenem HBr, which could lead to significant milestone payments if regulatory and commercialization efforts are successful.
-
Spero Therapeutics Inc (NASDAQ:SPRO) has sufficient cash and cash equivalents to fund operations into Q2 2026, providing financial stability for ongoing projects.
-
The Phase 3 PIVOT-PO trial for tebipenem HBr is designed to address a significant unmet need in the treatment of complicated UTIs, potentially reducing hospital stays by offering an oral alternative to IV therapy.
-
The company is conducting a pre-specified interim analysis for the Phase 3 trial of tebipenem HBr, with results expected in the second quarter of 2025, which could accelerate the development timeline if successful.
Negative Points
-
Spero Therapeutics Inc (NASDAQ:SPRO) reported a decrease in total revenue for 2024 compared to 2023, primarily due to reduced collaboration revenue from agreements with GSK and Pfizer.
-
The company experienced a significant increase in R&D expenses year-over-year, driven by increased clinical trial activity, which contributed to a net loss for the year.
-
The Phase 2A trial for SPR720 did not meet its primary endpoint, and there were dose-limiting safety signals, including cases of reversible Grade 3 hepatotoxicity.
-
Spero Therapeutics Inc (NASDAQ:SPRO) decided to discontinue development of SPR206, an IV-administered antibiotic, following a pipeline review and reprioritization.
-
The company reported a net loss of $68.4 million for the year ended December 31, 2024, compared to a net income in the previous year, indicating financial challenges.